Francesca Palandri/LinkedIn
Aug 17, 2026, 16:22
Francesca Palandri: Why Is Ruxolitinib Response So Heterogeneous in Myelofibrosis?
Francesca Palandri, Hematologist at IRCCS Sant’Orsola Polyclinic – Bologna University Hospital, shared on LinkedIn about a recent article she and Filippo Branzanti co-authored, published in Clinical Lymphoma Myeloma and Leukemia, adding:
”Why is ruxolitinib response so heterogeneous in myelofibrosis?
Our SOHO State of the Art review covers:
- Cytopenic vs. proliferative phenotype
- Dose intensity (the 1 modifiable factor)
- HMR mutations, RAS/CBL, cytogenetics
- Dynamic models RR6, iRR6, STR-PM
Moving from static baseline prognostication to response-driven precision medicine.”
Title: SOHO State of the Art Updates and Next Questions | Predictive Markers for Ruxolitinib in Myelofibrosis
Authors: Francesca Palandri, Filippo Branzanti
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 30, 2026, 15:58Bernhard Merget: New Frontiers in Thrombosis and Stroke Research
-
Sep 30, 2026, 15:39Ifeanyichukwu Ifechidere: The Molecular Orchestra of Primary Hemostasis
-
Sep 30, 2026, 15:28Reassessing the Benefit–Risk Balance of Extended Anticoagulation in Cancer Patients – ESC Working Group on Cardiovascular Pharmacotherapy
-
Sep 30, 2026, 15:07Chiranjeev Sharma: Targeting Factor XIa with the Synthetic Inhibitor SB-01
-
Sep 30, 2026, 14:41Bruna Gigante: Balancing Thrombosis and Bleeding in Cardiovascular Care
-
Sep 30, 2026, 14:13Ashok Choudhury: Portal Vein Thrombosis and Outcomes in Cirrhosis
-
Sep 30, 2026, 13:57Leslye Conde Bazán: When Conventional Imaging Is Not Enough – The Role of IVUS
-
Sep 30, 2026, 13:41Huda Salah Eldin: The Challenge of Balancing Antithrombotic Therapy After PCI
-
Sep 30, 2026, 13:29Abdus Salam: What Can CT Venography Reveal About the Veins?